Health

A recent study from Polish researchers has revealed some exciting news about toothpaste. They’ve developed a new formula without fluoride that works just as well as traditional fluoride toothpaste in preventing cavities. The secret ingredient? Hydroxyapatite, a mineral already known for helping with dental issues like sensitivity and periodontitis.

This new toothpaste was tested in a clinical trial lasting 18 months, and the results were impressive. People who used hydroxyapatite toothpaste were just as likely to stay cavity-free as those who used fluoride toothpaste.

Depression can feel like a never-ending battle, especially when traditional treatments like talk therapy or antidepressants don’t seem to help. But a recent study from Australia is offering a spark of hope—using a familiar drug in a new way.

A new study from The Lancet Psychiatry has uncovered some deeply troubling effects of conversion therapy on LGBTQ+ individuals in the U.S. It shows that people who go through this type of practice—especially when it targets both their sexual orientation and gender identity—face a much higher risk of mental health problems, including depression, PTSD, and suicidal thoughts or attempts.

Let’s break down what this means in simpler terms.

A major global study, co-led by experts from The University of Queensland and Harvard Medical School, has found that one in two people will experience a mental health disorder at some point in their lifetime. This research sheds light on the high prevalence of mental health issues and calls for more support and early intervention.

A groundbreaking new technology that blends human brain cells with computer circuits is set to transform the future of robots and AI. The "DishBrain" is a semi-biological chip developed by scientists at Monash University, and it’s already showing impressive potential in the world of artificial intelligence. Now, this exciting research has caught the attention of the military, earning a $407,000 grant to continue its development.

A promising new drug from Eli Lilly is making waves in Alzheimer’s research. The experimental treatment, called donanemab, has shown great potential in slowing down the progression of Alzheimer's disease, especially when used early in patients with mild symptoms.

In a recent study, researchers found that donanemab can slow the decline in memory and thinking skills by 60% if it’s started while patients are still only mildly impaired. The results are based on data from more than 1,700 patients and were presented at the Alzheimer's Association International Conference in Amsterdam.

Charles Brenner's challenge to the longevity industry, which is gaining momentum due to the promise of extending human life expectancy, centers around his skepticism of the claims made by prominent figures and the technologies they promote. A respected biochemist, Brenner has become known as a "longevity skeptic," despite his own groundbreaking work on nicotinamide riboside (NR), a compound linked to NAD+ production, which has shown benefits in aging mice. His concerns focus on the exaggerated promises made by many scientists and companies within the longevity field.

Imagine a tiny wearable device that can track your body’s inflammation levels just by analyzing your sweat. That’s exactly what a team of scientists at Caltech has created—a simple, noninvasive sensor that could make it easier for people with chronic conditions to monitor their health at home.

Imagine if your brain could tell you what song you’ll love before you even know it yourself. Thanks to a new study, we might be closer to that reality than ever.

Researchers in the U.S. have found a way to predict chart-topping songs with almost perfect accuracy — by analyzing brain activity while people listen to music. The results are turning heads in both the science and music worlds, with a whopping 97% accuracy in identifying hit songs. That’s a huge leap from the old methods, which barely scratched 50%.

Scientists in Australia have made an exciting discovery that could help people living with type 1 diabetes. In a recent study, they found a way to “reboot” certain cells in the pancreas so they start producing insulin again. And the surprising part? They used a cancer drug to do it.